Details for New Drug Application (NDA): 070918
✉ Email this page to a colleague
NDA 070918 describes NALBUPHINE HYDROCHLORIDE, which is a drug marketed by Abbott, Abbvie, Dr Reddys, Hospira, Igi Labs Inc, Rising, and Somerset Theraps Llc, and is included in seventeen NDAs. It is available from five suppliers. Additional details are available on the NALBUPHINE HYDROCHLORIDE profile page.
The generic ingredient in NALBUPHINE HYDROCHLORIDE is nalbuphine hydrochloride. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the nalbuphine hydrochloride profile page.
The generic ingredient in NALBUPHINE HYDROCHLORIDE is nalbuphine hydrochloride. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the nalbuphine hydrochloride profile page.
Summary for 070918
| Tradename: | NALBUPHINE HYDROCHLORIDE |
| Applicant: | Hospira |
| Ingredient: | nalbuphine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 070918
| Mechanism of Action | Competitive Opioid Antagonists Partial Opioid Agonists |
Medical Subject Heading (MeSH) Categories for 070918
Suppliers and Packaging for NDA: 070918
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 070918 | ANDA | Henry Schein, Inc. | 0404-9917 | 0404-9917-10 | 1 VIAL, MULTI-DOSE in 1 BAG (0404-9917-10) / 10 mL in 1 VIAL, MULTI-DOSE |
| NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 070918 | ANDA | Hospira, Inc. | 0409-1467 | 0409-1467-01 | 25 CARTON in 1 CASE (0409-1467-01) / 1 VIAL, MULTI-DOSE in 1 CARTON (0409-1467-61) / 10 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/ML | ||||
| Approval Date: | Feb 3, 1989 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
